BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177-189. [PMID: 30575405 DOI: 10.1080/14737140.2019.1559058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Azhar AF, Saporito RC, Jamerson J. Erythema multiforme after treatment with sorafenib. Proc (Bayl Univ Med Cent) 2021;34:380-1. [PMID: 33953468 DOI: 10.1080/08998280.2021.1877509] [Reference Citation Analysis]
2 Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00904-4] [Reference Citation Analysis]
3 Catalano A, Iacopetta D, Sinicropi MS, Franchini C. Diarylureas as Antitumor Agents. Applied Sciences 2021;11:374. [DOI: 10.3390/app11010374] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
4 Gudkov A, Shirokorad V, Kashintsev K, Sokov D, Nikitin D, Anisenko A, Borisov N, Sekacheva M, Gaifullin N, Garazha A, Suntsova M, Koroleva E, Buzdin A, Sorokin M. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Front Mol Biosci 2022;9:753318. [DOI: 10.3389/fmolb.2022.753318] [Reference Citation Analysis]
5 Tateo V, Manuzzi L, Parisi C, De Giglio A, Campana D, Pantaleo MA, Lamberti G. An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals (Basel) 2021;14:316. [PMID: 33915954 DOI: 10.3390/ph14040316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
7 Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
8 Sofer S, Lamkiewicz K, Armoza Eilat S, Partouche S, Marz M, Moskovits N, Stemmer SM, Shlomai A, Sklan EH. A genome-wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi-kinase inhibitors in hepatocellular carcinoma cells. FASEB J 2022;36:e22191. [PMID: 35147243 DOI: 10.1096/fj.202101507RR] [Reference Citation Analysis]
9 Huh KY, Hwang S, Park SY, Lim HJ, Jin M, Oh J, Yu KS, Chung JY. Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib. Pharmaceutics 2021;13:629. [PMID: 33925058 DOI: 10.3390/pharmaceutics13050629] [Reference Citation Analysis]
10 Wang B, Sun L, Wen M, Tan Y, Almalki WH, Katouah H, Kazmi I, Afzal O, Altamimi ASA, Al-Abbasi FA, Alrobaian M, Alharbi KS, Alenezi SK, Alghaith AF, Beg S, Rahman M. Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma. Saudi Pharm J 2021;29:843-56. [PMID: 34408545 DOI: 10.1016/j.jsps.2021.06.006] [Reference Citation Analysis]
11 Hałasa M, Łuszczki JJ, Dmoszyńska-Graniczka M, Baran M, Okoń E, Stepulak A, Wawruszak A. Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin-An Isobolographic Analysis in Breast Cancer In Vitro Models. Int J Mol Sci 2021;22:8573. [PMID: 34445277 DOI: 10.3390/ijms22168573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hu Y, Guo N, Yang T, Yan J, Wang W, Li X. The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer. Oxid Med Cell Longev 2022;2022:1458143. [PMID: 35028002 DOI: 10.1155/2022/1458143] [Reference Citation Analysis]
13 Caterino M, Pirozzi M, Facchini S, Zotta A, Sica A, Lo Giudice G, Rauso R, Varriale E, Ciardiello F, Fasano M. Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. Medicina 2022;58:666. [DOI: 10.3390/medicina58050666] [Reference Citation Analysis]
14 Ortega-Muelas M, Roche O, Fernández-Aroca DM, Encinar JA, Albandea-Rodríguez D, Arconada-Luque E, Pascual-Serra R, Muñoz I, Sánchez-Pérez I, Belandia B, Ruiz-Hidalgo MJ, Sánchez-Prieto R. ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. J Cell Mol Med 2021;25:10591-603. [PMID: 34655447 DOI: 10.1111/jcmm.16990] [Reference Citation Analysis]
15 Santonocito M, Zappulla C, Viola S, La Rosa LR, Solfato E, Abbate I, Tarallo V, Apicella I, Platania CBM, Maugeri G, D'Agata V, Bucolo C, De Falco S, Mazzone MG, Giuliano F. Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. Int J Mol Sci 2021;22:4404. [PMID: 33922399 DOI: 10.3390/ijms22094404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, Liang S. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacol Res 2021;170:105732. [PMID: 34139345 DOI: 10.1016/j.phrs.2021.105732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Li L, Cheng L, Sa R, Qiu X, Chen L. Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers. Crit Rev Oncol Hematol 2022;:103624. [PMID: 35150866 DOI: 10.1016/j.critrevonc.2022.103624] [Reference Citation Analysis]
18 Feng W, Cao W, Cui C, Pi X, Mi Y. Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/4996471] [Reference Citation Analysis]
19 Caballeria-Casals A, Micó-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Casillas-Ramírez A, Álvarez-Mercado AI, Gracia-Sancho J, Peralta C. Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde? Cells 2021;10:1421. [PMID: 34200439 DOI: 10.3390/cells10061421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tian Z, Niu X, Yao W. Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Front Oncol 2021;11:749083. [PMID: 34676173 DOI: 10.3389/fonc.2021.749083] [Reference Citation Analysis]
21 Dai X, Wang D, Zhang J. Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis 2021;26:385-414. [PMID: 34236569 DOI: 10.1007/s10495-021-01682-0] [Reference Citation Analysis]
22 Heppner DE, Eck MJ. A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Protein Sci 2021;30:1535-53. [PMID: 34008902 DOI: 10.1002/pro.4125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Karbownik A, Stachowiak A, Urjasz H, Sobańska K, Szczecińska A, Grabowski T, Stanisławiak-Rudowicz J, Wolc A, Grześkowiak E, Szałek E. The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. Pharmacol Rep 2020;72:254-9. [PMID: 32016844 DOI: 10.1007/s43440-019-00021-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N. TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:630429. [PMID: 33790903 DOI: 10.3389/fimmu.2021.630429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clin Cancer Res 2019;25:7320-30. [PMID: 31455680 DOI: 10.1158/1078-0432.CCR-19-0470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
26 Palomba F, Genovese D, Rampazzo E, Zaccheroni N, Prodi L, Morbidelli L. PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells. ACS Omega 2019;4:13962-71. [PMID: 31497714 DOI: 10.1021/acsomega.9b01699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 2022;11:2077898. [DOI: 10.1080/2162402x.2022.2077898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
29 Majewska A, Brodaczewska K, Filipiak-duliban A, Kajdasz A, Kieda C. miRNA Pattern in Hypoxic Microenvironment of Kidney Cancer—Role of PTEN. Biomolecules 2022;12:686. [DOI: 10.3390/biom12050686] [Reference Citation Analysis]
30 Wei J, Xia Y, Meng F, Ni D, Qiu X, Zhong Z. Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma. Biomacromolecules 2021;22:4814-22. [PMID: 34677048 DOI: 10.1021/acs.biomac.1c01103] [Reference Citation Analysis]
31 Lei GL, Fan HX, Wang C, Niu Y, Li TL, Yu LX, Hong ZX, Yan J, Wang XL, Zhang SG, Ren MJ, Yang PH. Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma. World J Gastroenterol 2021; 27(1): 55-68 [PMID: 33505150 DOI: 10.3748/wjg.v27.i1.55] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat 2021;57:100770. [PMID: 34175687 DOI: 10.1016/j.drup.2021.100770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 2021;54:e13009. [PMID: 33655556 DOI: 10.1111/cpr.13009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
34 Tian Z, Niu X, Yao W. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol 2020;10:1642. [PMID: 32984034 DOI: 10.3389/fonc.2020.01642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
35 Jiang W, Xia J, Xie S, Zou R, Pan S, Wang Z, Assaraf YG, Zhu X. Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resistance Updates 2020;50:100683. [DOI: 10.1016/j.drup.2020.100683] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
36 Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch C, König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Horm Metab Res 2021;53:149-60. [PMID: 33652491 DOI: 10.1055/a-1380-4154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang H, Jin C, Fang L, Sun H, Cheng W, Hu S. Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review. Cost Eff Resour Alloc 2020;18:1. [PMID: 31938024 DOI: 10.1186/s12962-019-0198-z] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Higuchi T, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Bouvet M, Tsuchiya H, Hoffman RM. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib. Cancer Genomics Proteomics 2021;18:637-43. [PMID: 34479916 DOI: 10.21873/cgp.20286] [Reference Citation Analysis]
39 Kim J, Park JH, Park SK, Hoe HS. Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice. Front Immunol 2021;12:684344. [PMID: 34122447 DOI: 10.3389/fimmu.2021.684344] [Reference Citation Analysis]
40 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Han H, Lin T, Fang Z, Zhou G. RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway. Biomed Res Int 2021;2021:6697476. [PMID: 33791378 DOI: 10.1155/2021/6697476] [Reference Citation Analysis]
42 Wan Y, Yan C, Gao H, Liu T. Small-molecule PROTACs: novel agents for cancer therapy. Future Medicinal Chemistry 2020;12:915-38. [DOI: 10.4155/fmc-2019-0340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Kong H, Zhang R, Jing Q, Liang Y, Zhuo Q, Li B, Zhang S, Zhu W, Zhao C. Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway. Microvasc Res 2022;143:104401. [PMID: 35750130 DOI: 10.1016/j.mvr.2022.104401] [Reference Citation Analysis]